Logo

Definiens IO-Panel

Nov 07, 2017

Definiens now offers its Immuno-Oncology Panel (IO-Panel) as part of its "Insights" services portfolio. The IO-Panel is designed to enable pharmaceutical immuno-oncology researchers to advance tissue-biomarker-dependent drug development and speed up clinical research. It combines Definiens' digital image analysis capabilites, powered by Tissue-Phenomics technology, which quantifies relevant spatial relations of different immuno and tumor cells within the context of the complete tissue architecture and tumor heterogeneity, the company said.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.